drinking on glp-1 shifts alcohol market dynamics | EY Why Hydration Matters More When

Launching oral GLP-1s requires more than extending injectable playbooks

Initially developed by Novo Nordisk in the 1990s, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective agonist of the GHS-R1a receptor (ghrelin receptor), responsible for stimulating pulsatile growth hormone secretion without the cross-side effects characteristic of non-selective GHRPs

Most people experience nausea within the first 48 hours after starting the medication or after each dose increase

Major Ingredients Water, Centella Asiatica Extract (25.3%), Glycerin, Cetyl Ethylhexanoate, Butylene Glycol, Polyglyceryl-3 Methylglucose Distearate, Niacinamide (20,000ppm), Beeswax, Stearic Acid, Sodium Polyacryloyldimethyl Taurate, Silica, Sodium Hyaluronate, Glyceryl Stearate, Butyrospermum Parkii (Shea) Butter, Macadamia Ternifolia Seed Oil, Hydrogenated Polydecene, Betaine, Glutathione (1,000ppm), Trehalose, Adenosine, Citric Acid, Trideceth-10, Disodium EDTA, Sodium Citrate, Nelumbo Nucifera Extract, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Saccharomyces Ferment, Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract, Hydrolyzed Collagen, Caprylic/Capric Triglyceride, Hydrogenated Lecithin, Xanthan Gum, Carbomer, Arginine, Squalane, Beta-Glucan, Dipropylene Glycol, Hippophae Rhamnoides Fruit Extract, Madecassic Acid, Asiaticoside, Asiatic Acid, Propanediol, Hydroxyacetophenone, 1,2-Hexanediol, Ethylhexylglycerin, Dipotassium Glycyrrhizate Ingredients subject to change at manufacturer's discretion